Understanding how a pump works.
BioMed Reports says some BB stk that deals withe the elderly is about to announce a huge contract.
Gene Maracel now has a weird online presense he has always danced on the edge- he publishes the story flat out- big contract coming....
(a) Biomedreports.com has put out a trading alert on ACAR. It said the company is close to a strategic partnership that could help drive its earnings. More than likely a major marketing partner. The company is also launching a major marketing initiative for is emergency service care center using its Pal unit to connect. It is the leading technological widget that is revolutinizing old age care.
(b) INVESTORâS ALERT: Watch ActiveCare
By Gene Marcial
June 9, 2010
There isnât much information available yet about a little known company called ActiveCare (ACAR), which develops personal emergency response devices for senior citizens and the sick or disabled. Currently trading over the counter at just more than $1 a share, the company integrates global positioning system and cellular phone technologies to develop devices that active senior citizens can use to alert a monitoring center that they fallen or otherwise need immediate medical or physical assistance.
The big story here is the company is close to signing a major contract with an insurance company that should dramatically increase its top and bottom lines. Some investors believe the deal could add more than $1 a share to earnings over the next 12 to 18 months. The company has only 14 million fully diluted shares outstanding. The contract could be a big boon to ActiveCare. Stay tuned.
>>>> You have to take these things is stride. That's a big promise from the boys. Unfortunately they are pushing another stock one I kind of like. I can't deny I made a killing once this year off the name so I'm afraid of pushing my luck. And indeed this name is coming through the same spin cycle--- Bio Med--- To Gene...
but this one has been upgraded by Goldman! Yup some cat in his basement named Goldman. That's like getting upgraded my Morgan Spurlock... or MS.
here we go- RNN
ted on admin on June 16, 2010 // Leave Your Comment
REXAHN PHARMACEUTICALS, INC.
(NYSE:AMEX -RNN)
Four Reasons Why Stock Should Move Higher
By Rob GoldmanIt has been exactly two months since our last Company Update (excludes a Research Alert in May) and we believe now is a good entry point to buy the stock and/or add to existing positions. Below we outline 4 reasons why we project that the stock could be markedly higher in the next 30 days.
Reason #1: News on June 18th
On Friday, June 18th, the FDA will vote on whether or not to approve the first âfemale Viagra pill.â The drug, known as Flibanserin, is made by German pharmaceutical giant Boehringer Ingelheim. The Company claims that the drug boosts womenâs sexual desire. While an approval would likely be welcomed by men nationwide, it may also provide a âlooking glassâ into Rexahnâs Zoraxel and Serdaxin drugs.
Flibanserinâs mechanism of action is based upon the manipulation of neurotransmitters that play a key role in sexual activity. Zoraxel is also a Central Nervous System-based (CNS) treatment whose mechanism acts as a dual serotonin and dopamine enhancer in the brain. And although Serdaxin is designed as an anti-depressant, it utilizes the same basic mechanism.
The Bottom Line: An FDA approval for this Female Viagra Drug gives us insight into how safety and efficacy of a sexual dysfunction treatment that has a similar basic mechanism of action is viewed by the FDA. An approval would enhance RNNâs standing. Plus, it would give us more confidence regarding potential Zoraxel approval and marketing and development relationships.
Reason #2: Fred Frank
Last week, Rexahn announced that it has hired Fred Frank, a noted investment banker with a long history and track record of mergers and acquisitions success. Investors did not correctly interpret the importance of this news, in our view.
The Bottom Line: Fred Frank is a wheeler-dealer extraordinaire. He is well-known on the Street for executing M&A. Interestingly, much of his work has been with companies much larger than RNN. The fact that he has taken on this assignment gives us great confidence that not only will RNN execute an investment/development/marketing deal with Big Pharma for Serdaxin or Zoraxel, but that it will be a favorable deal to the Company and shareholders. Finally, the timeline to execution may be sooner now as well.
Reason # 3: Teva
Rexahn has an all-encompassing development and milestone payment deal for the pre-clinical cancer treatment RX-3117.
The Bottom Line: It is that time of year. We expect that the next milestone payment (we estimate $3-4M) will occur at the turn of the quarter. This would no doubt have a positive impact on the stock.
Reason #4: The Share Price
The stock has drifted downward for several weeks on light volume, along with many other small biotechs. From the technical perspective, we think once it pushes through $1.20, it has little to no resistance until around $1.50.
The Bottom Line: The stock is basically at the same price as when we initiated coverage in February. Yet, Rexahn is in a much stronger position. The Company has announced favorable Phase IIa results for 2 drugs, announced Phase IIb launches, received patents for RX-3117, and raised funds through warrant conversion. The stock has been âbasingâ for some time and is a great at entry point at current levels, in our view.
Conclusion: The stock price and trading are incongruent with Rexahnâs current standing and prospects. New money is due soon from Teva, the Female Viagra trial may divert attention to Zoraxel, Serdaxin and Zoraxel trial sare due to start soon, and Phase IIa Archexin results will be upon us by yearâs end. Plus, we believe that the Fred Frank signing practically ensures a Big Pharma deal in some form during 2H10.
We reiterate our Speculative Buy rating and $4.00 target, although we believe that positive news could take it over $2.00 in the near term.
We initiated coverage of RNN on February 16, 2010 at a price of $1.22.
Cue Gene and a trading Alert*
Traders Alert: RNN June 14, 2010
Posted on admin on June 14, 2010 // Leave Your Comment
TRADERSâ ALERT: REXAHN UPDATE (June 14, 2010)
By Gene Marcial
Thereâs a new wrinkle at Rexahn Pharmaceuticals (RNN) that should be positive for the young biopharmaceutical company. On June 8, Rexahn announced the appointment of Frederick Frank, a veteran Wall Streeter and investment banker, as an independent consultant. Frank, vice chairman of investment firm Peter J. Solomon and known for his expertise in deal making, will advise Rexahn on a host of corporate matters, including mergers and acquisitions, to build up assets and enhance shareholder value.
Rexahn Chairman and CEO Chang Ahn says Frankâs expertise in healthcare and 50 years of investment banking focused on biotechnology will help the company in its quest for opportunities to expand and speed up the development of its various drugs in the pipeline. Rexahn focuses on developing therapies for cancer, central nervous system disorders, and sexual dysfunction
Currently, Rexahn has three products in phase 2 clinical trials: Archexin, Serdaxin, and Zoraxel. Rexahn plans to conduct a phase 2B clinical trial for Zoraxel in order to asses its efficacy in about 225 males, ranging in age from 18 to 65. The 12-week trials will start in the second half of 2010, and the results are expected by next year.
An earlier phase 2A clinical trials, completed in May 2009, demonstrated Zoraxel consistently outscored the International Index of Erectile Function (IIEF), and was found to be safe and well tolerated by the 39 patients in the clinical trials. The speculation is that Rexahn is in talks with one of the big pharmaceutical companies for a possible licensing of Zoraxel. Hence the hiring of Frank as a consultant.
A product being developed by Germanyâs Boehringer Ingleheim designed to enhance the female libido recently completed a phase 3 clinical trial. It has shown good efficacy in the studies. According to a report in The New York Post on May 27, the company is expected to submit the product to the FDA for review on efficacy and safety. Some analysts say that the Boehringer drug will help boost the appeal of Rexahnâs Zoraxel as they both use Seratonin with different doses for different treatments. .
However, Zoraxel also increases the level of dopamine. And it can be given 30 minutes prior tocontemplating sexual activity. Thr Boehringer product, called Flibaserin,,has to be taken daily. In that sense, Zoraxel has an advantage in terms of timing. If approved, Flibaserin reportedly could be on the market by year end.
If in fact Boerhinger will on the market that soon, it may prompt the Big Pharma companies to look at Rexahn and its Zoraxel to they can participate in that robust market. That would make Frankâs job easier. .
Among analysts who are bullish onRexahn are Rob Goldman of Goldman Small Cap Research and Elemer Piros of Rodman & Renshaw. On Friday June 11, 2010, shares of Rexahn closed at $1.16 a share, down from its 52-week high of $3.68 on Apr. 12, 2010.
>>> Note how Goldman in the basement is equated to Rodman & Ren! ~stoney